Skip to main content
OpenTrials
Completed

NCT Number: NCT05142410

Understanding Post-translational Modifications to Circulating Histones Via Mass Spectrometry in Pregnant Women Developing Pre-eclampsia: A Retrospective Study

This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47).

Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine.

Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications.

The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies.

The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pregnancy Related Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pre-Eclampsia Pregnancy Complications Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Nîmes University Hospital

Nîmes, Gard, 30900, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Not applicable as this study is on samples from a biobank. The inclusion criteria for the "GrossPath" cohort were:
  • pregnant women followed at Nîmes University hospital for normal pregnancy or pregnancy with placental vascular pathology (pre-eclampsia and/or intra-uterine growth retardation).
  • The patient must have given her free and informed consent and signed the consent form.
  • The patient must be a member or beneficiary of a health insurance plan
  • Only women are included
  • Patients are at least 18 years old

Exclusion criteria

  • Not applicable as this is a study on samples from a biobank. The non-inclusion criteria of the "GrossPath" cohort were :
  • twin pregnancies.

Treatment and study plan

Analysis of post-translational histone modifications via mass spectrometry

Diagnostic Test

During the "GrossHist" study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company [Bouvier and Fortier et al. 2021]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4).

Primary outcomes

  1. Presence of methylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.

  2. Presence of methylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.

  3. Presence of methylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.

  4. Presence of methylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.

  5. Presence of methylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.

  6. Presence of methylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.

  7. Presence of methylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.

  8. Presence of methylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.

  9. Presence of acetylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.

  10. Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.

  11. Presence of acetylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.

  12. Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.

  13. Presence of acetylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.

  14. Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.

  15. Presence of acetylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.

  16. Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.

  17. Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.

  18. Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.

  19. Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.

  20. Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.

  21. Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.

  22. Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.

  23. Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.

  24. Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.

  25. Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.

  26. Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.

  27. Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.

  28. Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.

  29. Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.

  30. Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.

  31. Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.

  32. Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.

  33. Presence of citrullination in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.

  34. Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.

  35. Presence of citrullination in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.

  36. Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.

  37. Presence of citrullination in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.

  38. Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.

  39. Presence of citrullination in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.

  40. Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.

Secondary outcomes

  1. Intensity of methylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  2. Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  3. Intensity of methylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  4. Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  5. Intensity of methylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  6. Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  7. Intensity of methylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  8. Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  9. Intensity of acetylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  10. Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  11. Intensity of acetylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  12. Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  13. Intensity of acetylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  14. Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  15. Intensity of acetylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  16. Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  17. Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  18. Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  19. Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  20. Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  21. Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  22. Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  23. Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  24. Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  25. Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  26. Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  27. Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  28. Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  29. Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  30. Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  31. Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  32. Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  33. Intensity of citrullination in histone H2A in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  34. Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  35. Intensity of citrullination in histone H2B in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  36. Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  37. Intensity of citrullination in histone H3 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  38. Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  39. Intensity of citrullination in histone H4 in pregnant women with normal pregnancies

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  40. Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia

    Time frame: At pregnancy term (max 41 weeks gestation)

    Mass spectrometry, quantitative

  41. Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  42. Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  43. Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  44. Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  45. Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  46. Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  47. Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  48. Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  49. Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  50. Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 of pregnancy

    YES/NO

  51. Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  52. Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  53. Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  54. Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: After 34 weeks of pregnancy

    YES/NO

  55. Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  56. Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  57. Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  58. Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  59. Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  60. Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  61. Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  62. Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  63. Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  64. Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  65. Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  66. Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  67. Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  68. Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  69. Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  70. Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  71. Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  72. Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  73. Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  74. Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  75. Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  76. Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  77. Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  78. Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  79. Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    YES/NO

  80. Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    YES/NO

  81. Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  82. Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  83. Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  84. Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  85. Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  86. Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  87. Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  88. Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  89. Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  90. Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  91. Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  92. Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  93. Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  94. Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  95. Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  96. Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  97. Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  98. Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  99. Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  100. Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  101. Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  102. Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  103. Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  104. Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  105. Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  106. Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  107. Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  108. Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 of pregnancy

    Mass spectrometry, quantitative

  109. Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  110. Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  111. Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  112. Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  113. Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  114. Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  115. Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  116. Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  117. Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  118. Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  119. Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  120. Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

  121. Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.

    Time frame: Before 34 weeks of pregnancy

    The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia early on will be recorded as YES/NO.

  122. Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.

    Time frame: 34 to 41 weeks of pregnancy

    The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia later on will be recorded as YES/NO.

  123. Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.

    Time frame: Before 34 weeks of pregnancy

    Mass spectrometry, quantitative

  124. Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.

    Time frame: 34 to 41 weeks of pregnancy

    Mass spectrometry, quantitative

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

A Retrospective Study Using Mass Spectrometry to Characterize Post-translational Modifications to Circulating Histones in Pregnant Women Developing Pre-eclampsia

Acronym: GHISPE

Important dates

Study start
2019
Primary completion
2020
Study completion
2023
First posted
Dec 2, 2021
Registry last updated
Jan 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.